Quantcast
Last updated on April 23, 2014 at 17:08 EDT

Latest EMD Serono Inc. Stories

2014-04-07 04:21:10

ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy EMD Serono,...

2014-04-01 08:28:55

ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 10(th) edition of the EMD Serono Specialty Digest(TM) at the 26(th) Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in Tampa, FL. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2013 and identifies common trends occurring across plans. The Digest is...

2014-04-01 08:28:06

- Agreement aims to identify biomarkers relevant to future therapies in the area of Systemic Lupus Erythematosus and Lupus Nephritis ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN)...

2013-12-17 08:30:27

-- The National MS Society through Fast Forward and EMD Serono provide funding of up to $1.3 million in 2013 to accelerate early-stage research in MS -- NEW YORK and ROCKLAND, Mass., Dec. 17, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society through Fast Forward and EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the fourth group of recipients to receive funding through their collaboration, which is designed to accelerate innovation...

2013-12-17 08:30:13

- EMD Serono and the National MS Society through Fast Forward provide funding of up to $1.3 million in 2013 to accelerate early-stage research in MS ROCKLAND, Mass. and NEW YORK, Dec. 17, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and the National Multiple Sclerosis Society through Fast Forward today announced the fourth group of recipients to receive funding through their collaboration, which is designed to accelerate innovation and commercial...

2013-12-16 08:26:43

- Gonal-f® RFF* Redi-ject(TM) (follitropin alfa injection) was approved for use by the FDA on October 17, 2013 ROCKLAND, Mass., Dec. 16, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Gonal-f(®) RFF Redi-ject(TM), a disposable pre-filled drug injector pen intended for the subcutaneous injection of a liquid formulation of Gonal-f(®) RFF, is now available in the U.S. for distribution. Gonal-f(®) RFF Redi-ject(TM) was...

2013-11-09 23:00:39

SITC and EMD Serono, Inc. collaborate to offer this new professional development opportunity for early career scientists involved in cancer immunotherapy. National Harbor, MD (PRWEB) November 09, 2013 Society for Immunotherapy of Cancer (SITC) in partnership with EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced a new one-year fellowship award designed to support the development of the next generation of immunotherapy experts with a vested interest in furthering...

2013-10-05 08:20:10

- Research grants reflect company's continuing commitment to multiple sclerosis (MS) community ROCKLAND, Mass. and COPENHAGEN, Denmark, Oct. 5, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29(th) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI). (Logo:...

2013-10-01 08:32:44

ROCKLAND, Mass., Oct. 1, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is the founding supporter of the newly launched Multiple Sclerosis (MS) Resource Centre website (http://multiplesclerosis.elsevierresource.com/) developed by Elsevier, B.V. of the Netherlands. EMD Serono helped established the MS Resource Centre through a $250,000 unrestricted grant to Elsevier, B.V. to develop and launch the website, which will provide high quality,...

2013-05-28 08:29:43

Certification marks second consecutive year J.D. Power and Associates recognizes MS LifeLines for providing an outstanding customer service experience ROCKLAND, Mass. and NEW YORK, May 28, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the MS LifeLines(® )call center earned re-certification for customer service excellence in providing support services to the multiple sclerosis (MS) community through...